Department of Surgery, Johns Hopkins University, Ross Building Room 765, Baltimore, MD 21205, USA.
Immunol Res. 2010 Jul;47(1-3):257-64. doi: 10.1007/s12026-009-8157-y.
Human leukocyte antigen (HLA) sensitization and ABO incompatibility continue to pose significant barriers to further expansion of live donor renal transplantation. However, the recent development of effective desensitization protocols and creative paired donation strategies demonstrates that the presence of circulating donor HLA-specific antibodies and the use of ABO incompatible organs should no longer be considered contraindications for renal transplantation. It is estimated that as many as 6,000 patients on the kidney transplant waiting list have incompatible living donors and could benefit from these treatments. Furthermore, as our understanding of these treatment modalities has improved, it is now possible to predict whether desensitization, kidney paired donation or a combination of both will provide an individual patient with their best chance for successful renal transplantation.
人类白细胞抗原（HLA）致敏和 ABO 不相容继续对活体供肾移植的进一步扩展构成重大障碍。然而，最近有效的脱敏方案和创造性的配对供体策略的发展表明，循环供体 HLA 特异性抗体的存在和 ABO 不相容器官的使用不应再被视为肾移植的禁忌证。据估计，多达 6000 名在肾脏移植等待名单上的患者有不相容的活体供体，可以从这些治疗中受益。此外，随着我们对这些治疗方式的理解的提高，现在可以预测脱敏、肾脏配对捐赠或两者的结合将为个体患者提供成功肾移植的最佳机会。
